1,112 results on '"Delaloge S"'
Search Results
2. Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)
3. Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022)
4. Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation
5. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
6. ESMO Guidance for Reporting Oncology real-World evidence (GROW)
7. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
8. Information needs on nutrition in link to cancer prevention among cancer patients, high-risk individuals and general population – A national cross-sectional study
9. Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer
10. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
11. Opérer ou non une lésion atypique du sein ? Prise en compte de l’anxiété dans l’aide à la décision partagée à partir d’une cohorte prospective de 300 patientes
12. P23 - Evolution des traitements de première ligne et survie en vie réelle des femmes âgées atteintes d'un cancer du sein métastatique RH+/HER2- par rapport aux femmes plus jeunes : résultats de l’étude observationnelle et nationale ESME
13. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
14. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
15. Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
16. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
17. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
18. T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
19. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
20. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial
21. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
22. ESMO Guidance for Reporting Oncology real-World evidence (GROW)
23. Mastectomie avec reconstruction mammaire immédiate : indications et techniques, algorithme de décision d’une reconstruction immédiate
24. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients
25. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
26. Preoperative radiotherapy in breast cancer patients: 32 years of follow-up
27. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
28. Traitement de première ligne et survie en vie réelle des femmes âgées atteintes d'un cancer du sein métastatique RH+/HER2- par rapport aux femmes plus jeunes : résultats de l’étude observationnelle et nationale ESME
29. 193MO Development of a deep learning model using a large real-world database to predict overall survival in patients with metastatic breast cancer (MBC)
30. 172P Early impact of a personalised cancer interception programme for women at non-genetic high risk of breast cancer (BC)
31. 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial
32. 163P Long-term assessment of secondary malignancies (2ndM) in women with breast cancer (BC) and germline TP53 mutations (gTP53m) treated with radiation therapy (RT)
33. 171MO Inflammatory profiling of individuals with germline TP53 mutations (gTP53m) and its relationship to subsequent cancer development
34. 200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)
35. 131P Efficacy of neoadjuvant letrozole and palbociclib in HER2-low vs HER2 zero luminal breast cancer: An analysis of the Unicancer Neopal phase II study
36. SA 4.1 Imaging, screening & surveillance for individuals with increased hereditary breast cancer risk
37. Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors : A collaborative work from ESMO real-world data and Digital Health Working Group
38. Real-world evidence contributions to European medicines agency's safety and efficacy evaluations of oncology targeted therapies between 2018-2022
39. ESMO Guidance for Reporting Oncology real-World evidence (GROW)
40. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
41. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
42. Douleur mammaire et imagerie
43. Breast pain and imaging
44. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
45. Deep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological Slides
46. 38P Single molecule localization microscopy for extracellular vesicles detection in cancer
47. 212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)
48. 467P Dose escalation of TAS-117 in patients with advanced solid tumors
49. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
50. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.